dc.creator | Andrews, Mónica | |
dc.creator | Soto, Néstor | |
dc.creator | Arredondo Olguín, Miguel | |
dc.date.accessioned | 2019-03-15T16:04:28Z | |
dc.date.available | 2019-03-15T16:04:28Z | |
dc.date.created | 2019-03-15T16:04:28Z | |
dc.date.issued | 2012 | |
dc.identifier | Rev Med Chile 2012; 140: 1377-1382 | |
dc.identifier | 00349887 | |
dc.identifier | 07176163 | |
dc.identifier | 10.4067/S0034-98872012001100001 | |
dc.identifier | https://repositorio.uchile.cl/handle/2250/165980 | |
dc.description.abstract | Background: The pharmacological action of metformin goes beyond mere
glycemic control, decreasing markers of inflammation and contributing to the
reduction of oxidative stress. Aim: To evaluate biochemical, anthropometric and
pro-inflammatory markers in obese type 2 diabetic patients treated or not with
metformin. Patients and Methods: Obese patients with type 2 diabetes were invited
to participate in the study if they were aged more than 40 years, were not receiving
insulin, did not have cardiovascular diseases and were not taking anti-inflammatory
drugs. A pharmacological history was taken and patients were stratified in two groups
whether they were using metformin or not. A fasting blood sample was obtained to
measure blood glucose, insulin, lipid levels, C reactive protein (hsCRP) and to isolate
peripheral blood mononuclear cells. RNA was isolated from these cells to measure
expression of tumor necrosis factor-α (TNF-α), Interleukin-6 (IL-6), nuclear factor
kappa-light-chain-enhancer of activated B cells (NF-κB), Toll-Like Receptor 2/4 (TLR
2/4) and beta-2-microglobulin (B2M). Results: Thirty participants were studied. Of
these, 16 subjects aged 54.4 ± 5.5 years were treated with metformin and 14 subjects
aged 54.9 ± 6.4 years did not receive the drug. Participants receiving metformin had
lower levels of hsCRP and lower mRNA relative abundance of TNF-α and TLR 2/4.
There were no differences in glucose levels or lipid profile between both groups. Conclusions:
Obese diabetic patients treated with metformin had lower levels of hsCRP
expression of TNF-α and TLR 2/4, than their counterparts not receiving the drug. | |
dc.language | sp | |
dc.rights | http://creativecommons.org/licenses/by-nc-nd/3.0/cl/ | |
dc.rights | Attribution-NonCommercial-NoDerivs 3.0 Chile | |
dc.source | Revista Médica de Chile | |
dc.subject | C-reactive protein | |
dc.subject | Inflammation | |
dc.subject | Metformin | |
dc.subject | Tumor necrosis factor-alpha | |
dc.title | Efecto de metformina sobre la expresión
del factor de necrosis tumoral-a,
los receptores Toll-like 2/4 y la PCR
ultra sensible en sujetos obesos
con diabetes tipo 2 | |
dc.type | Artículo de revista | |